Pionyr Immunotherapeutics

Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting novel target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.

Pionyr Immunotherapeutics headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $22.5B in funding across 64 round(s). With a team of 51-100 employees, Pionyr Immunotherapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Pionyr Immunotherapeutics, raised $8.0M. Discover more about their projects, partnerships, and impact on our platform.